Vaxart, Inc. (VXRT) Balance Sheet

The sharp contraction in the current ratio during 2025 suggests that the company's ability to cover short-term obligations is precarious without external funding injections. Investors should monitor the cash runway closely, as the current $50.7 million cash balance in 2026Q1 provides only a limited buffer against the high fixed costs of ongoing clinical trials.

While the current debt load appears manageable, the reliance on debt during periods of low cash suggests that the company lacks the internal cash flow durability to fund its R&D pipeline organically. This leverage profile warrants further investigation into the restrictive covenants that may accompany these debt instruments, which could limit future operational flexibility.

The persistent decline in equity quality suggests that the company is effectively consuming its capital base to advance its clinical pipeline. This trend implies that shareholders may face continued dilution risks if management is forced to issue additional equity to offset the erosion of retained earnings and maintain operations.